QTX-2101 + ATO for Acute Promyelocytic Leukemia

(QUATRO-APL Trial)

This trial tests a new combination of treatments for individuals with low-risk acute promyelocytic leukemia (APL), a type of blood cancer. Researchers aim to evaluate the effectiveness of an oral form of arsenic trioxide (ATO) combined with a standard drug called ATRA, compared to the usual intravenous form of ATO. The trial includes QTX-2101 as part of the new treatment combination. It targets individuals recently diagnosed with APL, confirmed by specific genetic tests. Participants must adhere to the study schedule and not have major heart issues or other severe medical conditions. As a Phase 3 trial, this study represents the final step before FDA approval, offering access to potentially groundbreaking treatment.

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that QTX-2101, a pill form of arsenic trioxide (ATO), is safe for patients. Studies suggest it matches the safety of the IV version. Thus, patients taking QTX-2101 can expect similar safety to those receiving ATO by IV.

Additionally, combining ATO with ATRA (all-trans retinoic acid) is well-tolerated and described as "highly effective and safe" for treating acute promyelocytic leukemia (APL). This combination eliminates the need for chemotherapy, which often causes more severe side effects.

Researchers are excited about QTX-2101 for acute promyelocytic leukemia (APL) because it offers a new way to deliver arsenic trioxide (ATO) orally, potentially making treatment more convenient than the standard intravenous (IV) ATO. Most existing treatments for APL, like IV ATO combined with all-trans-retinoic acid (ATRA), require administration in a clinical setting, which can be cumbersome for patients. The oral formulation of ATO in QTX-2101 could simplify the treatment process, reducing hospital visits and improving patient quality of life while maintaining the effectiveness of the therapy.

This trial will compare two treatment approaches for acute promyelocytic leukemia (APL). One arm will test the combination of QTX-2101 (oral arsenic trioxide, or ATO) with all-trans retinoic acid (ATRA) taken orally. Studies have shown that this all-oral combination is highly effective, with many patients achieving remission and over 95% showing significant improvement without chemotherapy. The other arm will use IV arsenic trioxide (ATO) combined with oral ATRA. Research suggests that oral administration of these drugs is as effective as IV administration, simplifying and increasing accessibility of treatment. Evidence also shows that both combinations are safe and well-tolerated, offering promising options for people with APL.¹³⁴⁶⁷